Kornimate/medical-research-clean huggingface dataset:
effectiveness of tai chi training on metabolic syndrome

Conditions: Metabolic Syndrome

Summary: metabolic syndrome (mets) is a serious public health problem in hong kong and worldwide. older adults, the age group with the highest prevalence of mets, may prefer specific exercise modalities that are suitable for their regular participation to manage mets. this project aims to evaluate the effectiveness of tai chi, a very suitable exercise for older adults, to alleviate mets in older population

purpose/objective: metabolic syndrome (mets) is a serious public health problem in hong kong and worldwide. older adults, the age by specific exercise modalities that are suitable for regular participation. this project aims to evaluate the effectiveness of tai chi to alleviate mets in older population. design \& methods: this study is a three-arm assesscer blinded randomized controlled trial. older adults aged 50 years or above with abdominal obesity will be randomly assigned to passive control, active control and tai chi groups. subjects assigned to tai chi and active control groups will receive a 12-week intervention of tai chi and generic fitness, respectively. no intervention will be given to the passive control group. outcome measures including waist circumference, blood pressure, blood glucose, triglyceride and high density lipoprotein-cholesterol will be assessed at baseline, post-intervention and follow-up (6 months after the end of intervention) assessments in all groups. hypotheses: we hypothesize that: 1) improvements of waist circumference and other indicators of mets are found in tai chi group but not in passive control group and 2) improvements of waist circumference and other indicators of mets are more profound in tai chi group than active control group.

Eligibility criteria:
inclusion criteria: * ethnic chinese * abdominal obese: meeting the defined criteria of international diabetes federation (idf) and national cholesterol education program (ncep) for abdominal obesity using asian-specific cut off (waist circumference ≥ 90 cm for male; ≥ 80 cm for female) exclusion criteria: * regularly practice moderate-intensity exercise or tai chi (\>3 times a week of \>30-min/ session) * serious medical and somatic condition that prevent participation in generic fitness/tai chi exercise * serious chronic diseases known to affect mobility (eg. neurological diseases, musculoskeletal disorder and autoimmune diseases) * under treatment for serious chronic diseases (eg. cancer treatment)

Keywords: metabolic syndrome waist circumference blood pressure triglyceride hdl cholesterol
study of low carbohydrate enteral nutrition in patients with bacterial septic shock

Conditions: Bacterial Sepsis

Summary: this pilot study aims to test the tolerability of low-carbohydrate enteral nutrition in patients with bacterial septic shock.

this study seeks to assess the tolerability of utilizing low-carbohydrate nutrition in patients admitted to the micu with bacterial septic shock. low carbohydrate feeds have been used before in the critical care setting and were well-tolerated.

Eligibility criteria:
inclusion criteria: 1. patients aged 18-65 admitted to the micu with a diagnosis of severe sepsis or septic shock 2. patients with 35 \> bmi \> 18.5 3. patients with serum pro-calcitonin \> 1 ng/ml in the first 24 hours of hospitalization exclusion criteria: 1. patients with chronic kidney disease as defined by glomerular filtration rate \ 6 months 2. patients with chronic liver disease as defined by radiographic or tissue evidence of cirrhosis or persistently abnormal liver function tests for \> 6 months 3. patients with current malignancies 4. patients with autoimmune disease on current immunotherapy 5. patients on corticosteroids at doses of prednisone or prednisone-equivalents \> 5 mg for \> 6 months 6. patients with weight-reduction surgeries 7. patients with positive viral studies in the first 24 hours of admission
predictive model identifies painful sedation-free colonoscopy

Conditions: Pain; Non-sedated; Colonoscopy

Summary: colorectal cancer is one of the most common cancers globally and a leading cause of cancer-related death. colonoscopy is the standard screening method for colorectal cancer, significantly reducing mortality rates. however, the pain experienced during the procedure is one of the main reasons people avoid getting a colonoscopy. if operators can identify patients who are more likely to feel pain before the procedure, operators can take steps to reduce their discomfort. previous research has developed a model to predict discomfort during colonoscopy, but this model have some limitations in clinical use. therefore, investigators plan to develop a new model that also predicts the likelihood of painful colonoscopies. this study aims to identify factors related to pain in non-sedated colonoscopy and create a more accurate prediction model to help reduce pain during the procedure. a total of 455 patients will be divided into two groups randomly for training and validation. participants meet the inclusion criteria for this study, and investigators will ask participants to participate voluntarily. if participants agree, investigators will collect some of participants basic information and medical history, and assess participants' pain during the procedure. participants will only need to follow the doctors' instructions, complete bowel investigators' preparation, and undergo the colonoscopy as usual. the data collection will not interfere with participants' regular care


Eligibility criteria:
inclusion criteria: 1. patients undergoing non-sedated colonoscopy at ningbo university affiliated hospital from september 2024 to september 2025. 2. age: patients aged 18 to 75 years. 3. voluntary participation: patients who voluntarily agree to participate in the study and have signed the informed consent form. exclusion criteria: 1. patients under 18 years old. 2. patients who are unwilling or unable to provide informed consent. 3. patients with malignant diseases, severe chronic heart or lung diseases, or those who have received treatment or radiation therapy for coronary artery or cerebrovascular events requiring hospitalization in the past 3 months. 4. patients with a history of colorectal resection or those with an incomplete colon. 5. patients who do not require reaching the ileocecal valve. 6. patients who have not completed bowel preparation or who have only used enemas for bowel cleaning. 7. patients with severe bowel obstruction or bowel perforation. 8. pregnant or breastfeeding women. -
treatment of apogeotropic horizontal canal benign paroxysmal positional vertigo

Conditions: HC-BPPV

Summary: the purpose of this study was to compare the immediate efficacies of each treatment maneuvers in treatment of apogeotropic horizontal canal benign paroxysmal positional vertigo (hc-bppv).

a randomized prospective study of patients with hc-bppv. patients with apogeotropic type of hc-bppv were randomized to one of each three treatment groups at their first clinic visit. these groups included the gufoni maneuver, head-shaking maneuver, and sham group in apogeotropic hc-bppv. responsiveness of treatment maneuver was determined by positioning maneuver immediately after each treatment method based on resolves of vertigo and positional nystagmus.

Eligibility criteria:
inclusion criteria: * a history of brief episodes of positional vertigo, * direction-changing horizontal nystagmus beating toward the uppermost (apogeotropic nystagmus) or undermost (geotropic nystagmus) ear in both the lateral head turning positions, * no spontaneous nystagmus during upright sitting position, and * absence of identifiable central nervous system disorders that could explain the positional vertigo and nystagmus. exclusion criteria: * central positional nystagmus with identifiable cns lesions that could explain the positional nystagmus

Keywords: bppv(benign paroxysmal positional vertigo) hc-bppv(bppv involving the horizontal semicircular canal) nystagmus treatment outcome horizontal canal benign paroxysmal positional vertigo
drug interaction with metformin

Conditions: Healthy Male and Female Subjects

Summary: the purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers


Eligibility criteria:
inclusion criteria: * healthy men and women, ages 18-45 with a body mass index of 18-32 kg/m2 exclusion criteria: * unwilling to use acceptable method of birth control * current or recent (within 1 month) smoker * abnormal liver function tests * presence of edema * history of diabetes mellitus * history of heart failure or renal insufficiency * history of chronic or recurrent urinary tract infections, or vulvovaginal mycotic infections * history of hepatitis c

Keywords: diabetes,nos
therapeutic resistance and clonal evolution assessed with liquid biopsy of nsclc patients in china

Conditions: Lung Neoplasms; Lung Cancer, Nonsmall Cell; Adenocarcinoma of Lung; Squamous Cell Lung Cancer

Summary: to evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact of the relative abundance of sensitizing / resistance mutations.

in the study, 500 advanced nsclc patients will be recruited. all the patients will receive biopsy genotype assay and circultating tumor dna (ctdna) liquid biopsy. patients who carry actionable egfr mutation, ros1 fusion, alk fusion or met exon 14 skipping mutation will receive tki treatment according to guidelines. during the tki treatment, every patients will take liquid biopsy assay to monitor the mutation status. the study will be ended when all the patients had a progressive disease (pd) in their targeted lesion.

Eligibility criteria:
inclusion criteria: * provision of informed consent * newly diagnosed and histological or cytological confirmed stage iiib-iv lung adenocarcinoma or non-smoking squamous cell carcinoma patients according to the ajcc staging system. the stage iv lung cancer and brain metastasis can be diagnosed by imaging and enhanced ct respectively * ecog performance status 0-2 with expected more than 6 months of survival time * willingness to comply with required protocols and give permission to use the data for clinical research and products development exclusion criteria: * patients have other primary cancers * patients have symptomatic brain metastasis, complications that are associated with brain metastasis or cognitive disorders * patients failed in either plasma or tissue sample qc

Keywords: next generation sequencing (ngs) tyrosine kinase inhibitor (tki) liquid biopsy egfr gene mutation
semperflo* pain management system in inguinal hernia repair

Conditions: Inguinal Hernia; Pain

Summary: this study will compare the clinical performance of the semperflo\* pain management system with another commercial pain relief system using 0.5% bupivacaine following unilateral, open, inguinal hernia repair procedures. \*trademark

pain will be evaluated up to 5 days after surgery subjects will be followed for 30 days after surgery.

Eligibility criteria:
inclusion criteria: * subject is a candidate for primary, non-emergent unilateral, open inguinal hernia repair procedure * subject is 18 years or older * subject must be willing to participate in the study, and provide informed consent to participate. exclusion criteria: * subjects undergoing recurrent hernia repair; * subjects who plan to undergo another elective surgical procedure prior to the completion of this study; * subjects with known allergy to bupivacaine; * subjects with immunodeficiency diseases (including known hiv); * subjects with any findings identified by the surgeon that may preclude conduct of the study; * subjects who are known current alcohol and/or drug abusers;
study safety and efficacy of bone marrow derived autologous cells for the treatment of diabetes mellitus.

Conditions: Diabetes Mellitus.

Summary: this study is single arm, single centre trial to check the safety and efficacy of bone marrow derived autologous mono nuclear cells (100 million per dose).trial to be conducted for 36 months in patients with diabetes mellitus in india,primary outcome measure are abolition or reduction of insulin by\>50 percentage by the end of 6 months of abmsct-any reduction in requirement of insulin dosage and improvement in hba1c level.

his study is single arm, single centre trial to check the safety and efficacy of bone marrow derived autologous mono nuclear cells (100 million per dose).trial to be conducted for 36 months in patients with diabetes mellitus in india,primary outcome measure are abolition or reduction of insulin by\>50 percentage by the end of 6 months of abmsct-any reduction in requirement of insulin dosage and improvement in hba1c level.

Eligibility criteria:
inclusion criteria: * patient should suffer from diabetes mellitus. * willingness to undergo bone marrow derived autologous cell therapy. * ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required informed consent form(icf) for the study. * ability and willingness to regular visit to hospital for protocol procedures and follow up exclusion criteria: * patient with history of immunodeficiency hiv+,hepatitis b ,hbv and history of life threatening allergic or immune -mediated reaction. the site of bone marrow aspiration potentially limiting procedure. alcohol and drug abuse / dependence. patients with history of hypertension and hypersensitive.

Keywords: diabetes mellitus stem cells [mncs ]
modulation of bifidocentric dysbiosis through bifidobacterium bifidum prl2010 supplementation in caesarian-born infants

Conditions: Disbiosis

Summary: this study is aimed to manipulate the composition of the intestinal flora of the infants born by caesarian section through the administration of the probiotic strain "bifidobacterium bifidum prl 2010", in order to evaluate its effects on gut dysbiosis during the first 6 month of life.

there has been increasing interest in the field of human microbiome, considering its impact on health and diseases. the gastrointestinal tract represents the most heavily inhabited organ with microorganisms, counting 10 times the total number of human cells; for this reason, the gut microbiome has recently been referred as a proper organ. intestinal microbial composition is unique for each individual and it is influenced by numerous factors, of which delivery mode is an important one with gestational age of the newborn, type of feeding and intrapartum or neonatal antibiotic therapy. recent reports suggest that dysbiosis secondary to delivery mode affects the subsequent regulation of immune response and may be associated with several pathologic conditions, for example allergic diseases or obesity. moreover, gut microbiome seems to impact on neurodevelopment during first six months of life. bifidobacteria is the most represented group of intestinal microbiota in the newborn, followed by enterobacteria, and it plays an important role in the infant gut. this includes the fundamental function performed by bifidobacterium bifidum: it supplies the nutritional material to the rest of the microbial community, particularly bifidobacterium breve and bifidobacterium longum infantis that are the other typical bifidobacteria of the newborn. it is a powerful metabolizer of the intestinal mucus and the hmos (human milk oligosaccharides) present in breast milk. thanks to its exocitable enzymes, the degradative catabolism occurs in the intestinal environment. thus, b. bifidum favour the increase in intestinal richness and biodiversity (9), which correlates with the host's state of health. however, bifidobacteria is reduced in infants born by cesarean delivery. aim of the study is to assess if the bifidobacterium bifidum prl2010 supplementation effectively ameliorat bifidocentric dysbiosis due to the delivery mode and we want to confirm this by analyzing fecal microbiota in caesarean birth infants.

Eligibility criteria:
inclusion criteria: * healthy infants born by caesarian delivery * parents informed written consent exclusion criteria * suspension of the administration of the probiotic strain for a period of time exceeding 7 days * interruption of the administration of the probiotic strain before the completion of the sixth month * replacement of bifidobacterium bifidum prl2010 with another strain * refusal to collect the fecal sample expressed by parents * major congenital birth deformities * acute illness at enrollment * any condition affecting food intake or metabolism * maternal mental and psychosomatic diseases
performance study of a non-invasive glucose monitoring device prototype

Conditions: Diabetes Mellitus

Summary: this clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

protocol consists of two parts: part a) subjects will collect spectral raman data on device every 15 minutes for 10 hours a day for five days. the five days will be distributed within a timeframe of ten days. a flash glucose monitor will be used as a comparator. in addition to this, four daily capillary blood glucose readings will be collected. part b) subjects will perform four daily measuring sessions in which optical raman readings are paired with capillary blood glucose comparator. measuring sessions are performed in subjects' own home while maintaining usual diabetes management routines. subjects will collect data for 30 days during a 60 days' period.

Eligibility criteria:
inclusion criteria: * male and female subjects 18 years of age or older * diabetic patients (all types), insulin requiring * skin phototype 1-4 exclusion criteria: * for female participants: pregnancy or subject is attempting to conceive or not willing and able to practice birth control during the study duration * for female participants: breastfeeding * subjects not able to understand and read danish * in investigator's opinion, subject is not able to follow instructions as specified in the protocol * rejection by optical screenings * participants not able to hold hand/arm steadily (including tremors and parkinson's disease) * diagnosed with reduced circulation * extensive skin changes, tattoos or diseases on probe application site * known allergy to medical grade alcohol * known allergy to adhesives, applicable to subjects in rsp-13-01 * systemic or topical administration of glucocorticoids for the past 7 days * subjects undergoing dialysis treatment * medical history or any condition that may, in the opinion of the investigator, compromise the subject's ability to participate * concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff. * participants currently enrolled in another study

Keywords: non-invasive glucose monitoring raman spectroscopy
virtual reality - a new vision on pain

Conditions: Chronic Pain; Pain, Chronic; Musculoskeletal Disorder; Musculoskeletal Pain; Musculoskeletal Diseases or Conditions; Musculoskeletal Neck Pain; Back Pain

Summary: the purpose of the project is to investigate if the use of virtual reality (vr) technology with pre-programmed proprietary software can provide better treatment for patients with long-term pain conditions. this is investigated in this pilot study conducted on patients referred to outpatient treatment at the division of physical medicine and rehabilitation. the pilot study will lay the foundation for a follow-up study (rct). the effect of vr are evaluated by patient reporting forms; before start-up and 3 months after startup. patients included in the study receive standard treatment supplemented with the use of vr technology. the therapists involved will be interviewed to examine their experiences with the use of the vr-technology in the treatment of patients. vr technology can potentially contribute to better treatment (e.g. measured in outcomes such as activity, sleep problems, pain intensity, quality of life). moreover we expect that a vr-assisted treatment to be more cost-effective and increased availability regardless of geography and demography.


Eligibility criteria:
inclusion criteria: * pain duration \> 3 moths * master norwegian spoken language exclusion criteria: * history of malignant disease * pain duration \< 3 months * does not master norwegian spoken language * epilepsy

Keywords: virtual reality vr long lasting pain long-term
role of platelets in the pathophysiology of systemic lupus

Conditions: Systemic Lupus Erythematosus; Systemic Scleroderma Meeting; ANCA Vasculitis; Inflammatory Myositis; Gougerot-Sjögren Syndrome; Rheumatoid Arthritis

Summary: blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (sle), but also from other immunomediated diseases (scleroderma, vasculitis, myositis, gougerot-sjögren's and rheumatoid arthritis) in cases of high disease activity. once activated, platelets express adhesion molecules such as p-selectin on their surface, enabling them to interact physically with immune cells. in a recent work, we identified that activated platelets from lupus patients interact with regulatory t cells and block their regulatory function, thus participating in the deregulated activation of the immune system in sle. in addition, inhibition of platelet-immune cell interactions by an anti-p-selectin antibody improved les symptoms in two mouse models. the aim of this work is to investigate other potential platelet-immune cell interactions in patients with sle, in comparison with other autoimmune diseases (systemic scleroderma, anca vasculitides, inflammatory myositis, gougerot-sjögren syndrome and rheumatoid arthritis). this study could lead to a better understanding of the role of platelets in the pathophysiology of autoimmune diseases, identify new biomarkers of activity, and assess the potential of new therapeutic avenues in these diseases, such as platelet targeting.


Eligibility criteria:
inclusion criteria: * patients between 18 and 70 years of age * patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary) * patient able to understand the aims and risks of research * patient having signed and dated an informed consent form * patient for whom the diagnosis of at least one of the following pathologies has been confirmed: * systemic lupus erythematosus meeting acr/eular 20195 classification criteria. * systemic scleroderma meeting acr/eular 20136 classification criteria. * anca vasculitis according to eular/acr 2022.7-9 classification criteria. * inflammatory myositis according to eular/acr 201710 classification criteria. * gougerot-sjögren syndrome according to eular/acr 2016 classification criteria11. * rheumatoid arthritis according to acr/eular 201012 classification criteria. exclusion criteria: * patient in exclusion period (determined by a previous or current study) * inability to give patient informed consent (patient in emergency or immediate life-threatening situation) * patient under court protection * patient under guardianship or curatorship

Keywords: platelets pathophysiology systemic lupus